TECHNOLOGY & PRODUCT IN-LICENSING

Technology & Product In-Licensing

Sourcing Innovation. De-Risking Growth. Accelerating Value.

In-licensing is a critical strategy for pharmaceutical, biotechnology, and life sciences companies seeking to expand pipelines, access novel technologies, and drive growth without internal R&D constraints. However, identifying the right assets—and structuring the right deal—requires deep scientific, clinical, regulatory, and commercial insight.

Our advisory platform provides end-to-end in-licensing support, combining strategic sourcing, rigorous due diligence, and deal execution expertise.

Core Capabilities

1. Asset & Technology Sourcing

• Identification of high-potential therapeutic assets and platforms
• Global scouting across biotech, academia, and emerging innovators
• Alignment with client pipeline, therapeutic focus, and strategy

2. Scientific & Clinical Evaluation

• Mechanism of action and biological rationale assessment
• Preclinical and clinical data review
• Differentiation vs. standard of care and competing assets

3. Commercial & Market Assessment

• Market size, unmet need, and competitive landscape
• Target product profile (TPP) development
• Revenue potential and lifecycle value modeling

4. Regulatory & Development Feasibility

• Clinical development pathway optimization
• Regulatory risk assessment (FDA, EMA, global pathways)
• Time-to-market and probability-of-success analysis

5. Financial Valuation & Deal Structuring

• Asset valuation (rNPV, risk-adjusted modeling)
• Benchmarking against comparable licensing deals
• Structuring milestones, royalties, and economics

6. Due Diligence Execution

• Integrated scientific, clinical, CMC, and regulatory diligence
• Identification of key risks and value drivers
• Red flag analysis and mitigation strategies

7. Transaction Support

• Negotiation strategy and support
• Term sheet and agreement review
• Cross-functional alignment through deal closing

Where We Add Value

• Improved asset selection → Focus on high-probability, high-value opportunities
• Reduced risk → Deep diligence across all development dimensions
• Faster execution → Streamlined evaluation and decision-making
• Stronger deals → Optimized financial and strategic terms

Typical Clients

• Pharmaceutical companies expanding pipelines
• Biotechnology companies seeking platform or asset growth
• Life sciences investors (VC, PE, family offices)
• Strategic acquirers and partners

Example Use Cases

• In-licensing a Phase II oncology asset to strengthen pipeline
• Acquiring a novel biologics platform from an academic spinout
• Evaluating multiple CNS assets for portfolio prioritization
• Supporting cross-border licensing transactions

Investor Soundbite (Slide-Ready)

“We help life sciences companies identify, evaluate, and secure high-value assets through rigorous scientific diligence and strategic deal execution.”

Number of companies: 4
Number of contacts: 4

Back to Home